Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRM: Olmesartan vs Atenolol on Carotid Atherosclerosis in Hypertensive Patients
2009-013342-92Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of olmesartan in essential hypertension and carotid atheroma (CAS) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in carotid plaque volume at 78 weeks. Started Dec 2009; status: completed.
02
Drugs
olmesartan
03
Conditions
essential hypertensioncarotid atheroma (CAS)
Beyond the preview
Go deeper on 2009-013342-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013342-92.